Cargando…

PPARG as therapeutic target for antifibrotic therapy

Detalles Bibliográficos
Autores principales:	Ghallab, Ahmed, Seddek, Abdellatief
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105936/ https://www.ncbi.nlm.nih.gov/pubmed/32256268 http://dx.doi.org/10.17179/excli2020-1136

Ejemplares similares

Liver fibrosis causes periportalization of lobular zonation
por: Seddek, Abdellatief
Publicado: (2019)

Use of antifibrotic drugs in familial interstitial pneumonia: analysis of one family
por: Estrella, Deborah dos Reis, et al.
Publicado: (2021)

Anticancer activity of luteolin glycosides
por: Ghallab, Ahmed
Publicado: (2020)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment
por: Ghallab, Ahmed
Publicado: (2014)

In vitro test systems and their limitations
por: Ghallab, Ahmed
Publicado: (2013)

TGR5 regulates portal perfusion pressure of the liver
por: Ghallab, Ahmed
Publicado: (2019)

Sebaceous gland reprogramming with a single gene, PPARG, and small molecules
por: Liu, Yiqiong, et al.
Publicado: (2023)

PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs
por: Li, De-Hui, et al.
Publicado: (2023)

The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications
por: Gold, Philip W.
Publicado: (2021)

Antifibrotic activity a fermentation filtrate of Ganoderma lucidum
por: Kwon, Sang-Chul, et al.
Publicado: (2011)

Adoption of Antifibrotic Medications: A Closer Look at the Data
por: White, Eric S., et al.
Publicado: (2021)

The Genetics of PPARG and the Skeleton
por: Ackert-Bicknell, Cheryl, et al.
Publicado: (2006)

Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
por: Dempsey, Timothy M., et al.
Publicado: (2021)

Identification of Novel Ligands for Targeted Antifibrotic Therapy of Chronic Pancreatitis
por: Hung, Jessica, et al.
Publicado: (2021)

PPARG is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target
por: Pleniceanu, Oren, et al.
Publicado: (2017)

Antifibrotic drugs as therapeutic tools in resistant melanoma
por: Sanchez‐Laorden, Berta, et al.
Publicado: (2022)

Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids
por: Islam, Md Soriful, et al.
Publicado: (2021)

Antifibrotic therapy to normalize the tumor microenvironment
por: Hauge, Anette, et al.
Publicado: (2020)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016)

Antifibrotic Therapies: Will We Ever Get There?
por: Thompson, Alexander James, et al.
Publicado: (2010)

Antifibrotics in India
por: Dhar, Raja
Publicado: (2019)

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma
por: Ran, Yunsheng, et al.
Publicado: (2023)

PPARG: A Novel Target for Yellow Tea in Kidney Stone Prevention
por: Su, Mingjie, et al.
Publicado: (2023)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

The Elusive Antifibrotic Macrophage
por: Adhyatmika, Adhyatmika, et al.
Publicado: (2015)

PPARG Binding Landscapes in Macrophages Suggest a Genome-Wide Contribution of PU.1 to Divergent PPARG Binding in Human and Mouse
por: Pott, Sebastian, et al.
Publicado: (2012)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail, Mona H, et al.
Publicado: (2011)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
por: Jangra, Anshika, et al.
Publicado: (2022)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

Anticytokine Therapies in Severe Coronavirus Disease 2019 Should Be Informed by Detailed Inflammatory Profiling and Specific Therapeutic Targets
por: Slessarev, Marat, et al.
Publicado: (2020)

PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma
por: Shi, Shunbin, et al.
Publicado: (2020)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Deciphering the Antifibrotic Property of Metformin
por: Septembre-Malaterre, Axelle, et al.
Publicado: (2022)

The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis
por: Ding, Xiaoying, et al.
Publicado: (2020)

Genetic Variability of RXRB, PPARA, and PPARG in Wegener's Granulomatosis
por: Wieczorek, Stefan, et al.
Publicado: (2009)

PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis
por: Sabatino, Lina, et al.
Publicado: (2012)

Association of FTO and PPARG polymorphisms with obesity in Portuguese women
por: Carlos, Fábio Ferreira, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ns5chl7m6bq4aa669ub0siskns